- Home
- IMUX vs GECC Comparison
IMUX vs GECC Comparison
Compare IMUX & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- GECC
- Stock Information
- Founded
- IMUX 2016
- GECC 2016
- Country
- IMUX United States
- GECC United States
- Employees
- IMUX N/A
- GECC N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- IMUX Health Care
- GECC Finance
- Exchange
- IMUX Nasdaq
- GECC Nasdaq
- Market Cap
- IMUX 100.0M
- GECC 121.9M
- IPO Year
- IMUX N/A
- GECC N/A
- Fundamental
- Price
- IMUX $1.07
- GECC $10.67
- Analyst Decision
- IMUX Strong Buy
- GECC
- Analyst Count
- IMUX 6
- GECC 0
- Target Price
- IMUX $12.67
- GECC N/A
- AVG Volume (30 Days)
- IMUX 885.0K
- GECC 35.8K
- Earning Date
- IMUX 02-20-2025
- GECC 02-27-2025
- Dividend Yield
- IMUX N/A
- GECC 13.59%
- EPS Growth
- IMUX N/A
- GECC N/A
- EPS
- IMUX N/A
- GECC 0.65
- Revenue
- IMUX N/A
- GECC $39,468,000.00
- Revenue This Year
- IMUX N/A
- GECC $18.56
- Revenue Next Year
- IMUX N/A
- GECC $5.85
- P/E Ratio
- IMUX N/A
- GECC $16.40
- Revenue Growth
- IMUX N/A
- GECC 16.86
- 52 Week Low
- IMUX $0.97
- GECC $9.55
- 52 Week High
- IMUX $2.11
- GECC $11.31
- Technical
- Relative Strength Index (RSI)
- IMUX 45.08
- GECC 55.96
- Support Level
- IMUX $0.99
- GECC $10.20
- Resistance Level
- IMUX $1.09
- GECC $11.09
- Average True Range (ATR)
- IMUX 0.06
- GECC 0.31
- MACD
- IMUX -0.00
- GECC 0.04
- Stochastic Oscillator
- IMUX 39.89
- GECC 62.83
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.